-

CEUS Expert Asks: Does Your Dog Kiss You?

CHICAGO--(BUSINESS WIRE)--A medical ultrasound conference may be the last place physicians expected to be asked: Does your dog kiss you?

But that’s exactly the question asked Thursday during a presentation in Chicago on the benefit of using contrast enhanced ultrasound (CEUS) to resolve a range of medical problems including the identification of a tapeworm that is increasingly migrating from coyotes to dogs to humans, causing a potentially fatal liver mass.

Dr. Stephanie Wilson, a radiologist at the University of Calgary, said that CEUS was able to quickly identify the tapeworm-induced liver masses in four patients who were emergently sent to surgery and survived. Dr. Wilson spoke at the 38th annual Advances in Contrast Ultrasound conference and is co-president of the International Contrast Ultrasound Society.

“These masses are fortunately still rare but they require aggressive surgery, and conventional tests for the presence of tapeworm eggs can take many weeks,” she explained.

But we are so accustomed to using CEUS as a versatile and reliable problem-solving tool, so we naturally turned to CEUS when we encountered an upsurge of tapeworms in our area.”

Physicians more typically use ultrasound contrast agents to diagnose heart and vascular disease, identify and characterize tumors, monitor chronic gastro-intestinal diseases, evaluate other serious medical conditions and monitor therapy.

Unlike contrast agents used for MR or CT, ultrasound contrast agents do not contain dye, create no known risk of kidney damage or deposit of contrast media in the brain, and do not expose patients or hospital staff to ionizing radiation.

The conference in Chicago drew CEUS experts from North America, Europe, China, Japan, Israel and Brazil.

Ultrasound contrast agents are manufactured and sold by Bracco, Lantheus and GE Healthcare.

ABOUT ICUS:

The International Contrast Ultrasound Society (ICUS) is a nonprofit medical society dedicated to advancing the safe and medically appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care globally. Membership in ICUS is available free of charge and there is no fee for ICUS CME-accredited educational programs, newsletters or other resources.

To join ICUS and learn more about CEUS, download ICUS Connect and visit the ICUS website (www.icus-society.org).

Contacts

International Contrast Ultrasound Society
Linda Maiman Feinstein, Advisor -- 847-624-1844 or 312-876-2563, Linda.Feinstein@Dentons.com
Robin J. Adams, Director of Communication -- 202-408-3946, Robin.Adams@Dentons.com

International Contrast Ultrasound Society


Release Summary
Does your dog kiss you? This was asked in a presentation on CEUS resolving medical problems including tapeworm causing a potentially fatal liver mass
Release Versions

Contacts

International Contrast Ultrasound Society
Linda Maiman Feinstein, Advisor -- 847-624-1844 or 312-876-2563, Linda.Feinstein@Dentons.com
Robin J. Adams, Director of Communication -- 202-408-3946, Robin.Adams@Dentons.com

More News From International Contrast Ultrasound Society

CMS Doubles Payment for Contrast-Enhanced Ultrasound Scans

CHICAGO--(BUSINESS WIRE)--Payment for certain contrast-enhanced ultrasound (CEUS) imaging procedures will double under a newly assigned billing code, according to an announcement by the International Contrast Ultrasound Society (ICUS) which advocated for the reimbursement upgrade. The change, published in the Federal Register today and effective January 1, 2026, will increase non-cardiac CEUS reimbursement from $170.02 to $358.35. It also reassigns non-cardiac CEUS to the same billing code used...

Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors

CHICAGO--(BUSINESS WIRE)--Contrast enhanced ultrasound (CEUS) is superior to contrast magnetic resonance (MR) and computed tomography (CT), and offers 100% sensitivity and specificity, for finding residual or recurrent kidney tumors in patients who have had a kidney-sparing procedure, according to a new study announced today at the 39th annual International Bubble Conference in Chicago. The study assessed 193 kidney lesions in 188 patients at two medical centers over approximately six years, ac...

New Studies Show Microbubble Ultrasound Contrast Agents Improve Liver Tumor Response to Radiotherapy and Survival

CHICAGO--(BUSINESS WIRE)--Two new clinical trials show that microbubble ultrasound contrast agents safely and effectively improve liver tumor responses to radiotherapy and patient survival, according to results announced today by Dr. John Eisenbrey, professor of radiology at Thomas Jefferson University, at the 39th annual International Bubble Conference in Chicago. One study found that patients with aggressive intrahepatic cholangiocarcinoma (ICC) and liver metastasis showed a greater than 50%...
Back to Newsroom